COVID-19

Information about treatment availability and patient assistance programs are below. For all other guidance, please refer to the CDC webpage COVID-19 Treatment Clinical Care for Outpatients.

Paxlovid
Patient Assistance Program:

• Through December 31, 2024, individuals covered under federal programs, such as Medicare or Medicaid, and uninsured patients are eligible for the PAP and can receive Paxlovid at no cost. This includes all patients publicly insured through Medicare (with or without Part D, Part B, or Part C and inclusive of Medicare Advantage), Medicaid/CHIP, TRICARE, and patients insured through the VA Community Care Network.
• Participating PAP dispensing sites will be reimbursed for any product dispensed, along with a dispensing fee.
• Retail pharmacies that would like to learn more about participating in the USG PAP can email the program vendor at PharmacyNetworkContract102101@assistrx.com.
• Paxlovid Patient Assistance Programs are available for Medicare, Medicaid and uninsured patients. More information on these programs can be accessed at: Paxlovid.com for patients and Paxlovid.pfizerpro.com for providers.
• A Paxlovid Co-Pay is available for patients with commercial insurance. Information regarding this program is available at: https://www.paxlovid.com/enroll-in-co-pay-program.

Remdesivir
Hospital ordering process:

• AmerisourceBergen Specialty Distribution: 1-800-746-6273 or email remdesivir@amerisourcebergen.com
• Cardinal Specialty: 1-855-855-0708
• McKesson Plasma: 1-877-625-2566

• AmerisourceBergen Specialty: 1-800-746-6273 or C19therapies@AmerisourceBergen.com
• Cardinal Specialty: 1-855-855-0708 or GMB-SPD-CSORDERENTRY@cardinalhealth.com
• Therapeutics locator: HHS is asking providers who administer outpatient Veklury (remdesivir) to add their infusion site to the COVID-19 Therapeutics Locator in order to improve public awareness and product access. Infusion sites can learn more and opt into the therapeutics locator here.

Molnupiravir (Lagevrio)
Lagevrio (Molnupiravir) EUA is still active and EUA Labeled. Lagevrio may still be dispensed to patients. Please refer to the searchable database to determine the accurate product expiry: COVID-19 Therapeutic Product Expiration.

Availability

• For commercial product, please visit www.merckorders.com or call the Merck Order Management Center at 800-MERCK-RX (800-637-2579).
  

Patient Assistance Program:

• The Merck Patient Assistance Program (a 501c3 non-profit organization) provides Lagevrio free of charge to patients who meet its eligibility criteria and who, without assistance, could not otherwise afford the product.
• This product is ONLY available through an URGENT NEED request. Health Care Providers must call 800-727-5400 and tell the program representative that they are making an Urgent Need Request for LAGEVRIO.
• You may also check eligibility on MerckHelps.
• Merck is also operating a Lagevrio Co-Pay Savings Program. Through this program, eligible privately insured patients may save on their out-of-pocket costs for their prescriptions for Lagevrio.

Pemivibart (Pemgarda)
Pre-exposure prophylaxis medication is available for some people who are moderately or severely immunocompromised. Visit the CDC webpage for more information.